Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Human Insulin NPH
Drug: LY2605541
Drug: Oral Antihyperglycemic Medications (OAM)

First Posted Date: 2013-02-13

Last Posted Date: 2018-05-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 641

Registration Number: NCT01790438

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Teruel, Spain

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Necitumumab
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2013-02-11

Last Posted Date: 2016-06-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 61

Registration Number: NCT01788566

Locations: 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan

A Study of LY2624803 in Japanese Participants With Transient Insomnia

Phase 1

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Drug: LY2624803 - Solution
Drug: LY2624803 - Capsule
Drug: Placebo - Solution
Drug: Placebo - Capsule

First Posted Date: 2013-02-06

Last Posted Date: 2016-01-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT01784614

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sagamihara, Japan

A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: LY2605541
Drug: Insulin Glargine

First Posted Date: 2013-02-05

Last Posted Date: 2019-03-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 76

Registration Number: NCT01784211

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany

A Study of LY2624803 in Participants With Transient Insomnia

Phase 1

Completed

Conditions: Transient Insomnia

Interventions: Drug: LY2624803 - Capsules
Drug: Zolpidem - Tablets
Drug: Placebo - Capsules
Drug: Placebo - Tablets

First Posted Date: 2013-01-30

Last Posted Date: 2013-01-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 32

Registration Number: NCT01779830

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rouffach, France

Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Ixekizumab Prefilled Syringe
Drug: Ixekizumab Auto-Injector

First Posted Date: 2013-01-28

Last Posted Date: 2019-09-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 204

Registration Number: NCT01777191

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ponce, Puerto Rico

A Study of Two Dosage Forms of LY2886721 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: LY2886721 in a Capsule
Drug: LY2886721 in an orally disintegrating tablet (ODT)

First Posted Date: 2013-01-25

Last Posted Date: 2019-07-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 26

Registration Number: NCT01775904

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Human Regular U-500 Insulin

First Posted Date: 2013-01-24

Last Posted Date: 2015-09-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 325

Registration Number: NCT01774968

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico

Study of LY3016859 in Participants With Diabetic Nephropathy

Phase 1

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: LY3016859
Drug: Placebo

First Posted Date: 2013-01-24

Last Posted Date: 2019-09-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 60

Registration Number: NCT01774981

Locations: 🇺🇸
Northeast Clinical Research Center, Bethlehem, Pennsylvania, United States
🇺🇸
Innovative Research of West Florida, Clearwater, Florida, United States
🇺🇸
Southeast Renal Research Institute, Chattanooga, Tennessee, United States

and more 4 locations

Comparison of Insulin Mix25 Versus Mix50

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin Lispro Mix50
Drug: Insulin Lispro Mix25

First Posted Date: 2013-01-23

Last Posted Date: 2015-05-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 403

Registration Number: NCT01773473

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy